Table 2 Number of identified PIMs and annual prevalence of use according to different criteria
Criteria | PIMsa identified | PIMs per person | Prevalence in 2017, % | Prevalence in 2018, % | Prevalence in 2019, % | Overlap between Meds75+ and other criteria %b |
|---|---|---|---|---|---|---|
Meds75+ database (Finland) | 91 | 1–13 | 33.6 | 32.7 | 30.4 | – |
Beers criteria (USA) | 79 | 1–17 | 57.0 | 56.4 | 55.3 | 57.4 |
EU(7)-PIM list (Estonia, Finland, France, Germany, the Netherlands, Spain and Sweden) | 128 | 1–16 | 39.9 | 38.9 | 37.5 | 72.2 |
Indicators for Quality of Drug Therapy in the elderly (Sweden) | 28 | 1–8 | 17.0 | 16.2 | 15.7 | 99.1 |
Laroche criteria (France) | 38 | 1–7 | 14.2 | 13.1 | 10.7 | 95.2 |
NORGEP-NH (Norway) | 29 | 1–11 | 36.0 | 34.9 | 33.7 | 65.3 |
PRISCUS list (Germany) | 35 | 1–8 | 24.0 | 22.9 | 20.6 | 72.2 |
Red-Yellow-Green list (Denmark) | 38 | 1–9 | 30.1 | 29.6 | 28.9 | 56.9 |
STOPP(/START) (Ireland) | 65 | 1–17 | 52.1 | 51.7 | 50.8 | 57.9 |